Protective role of pravastatin in the pathogenesis of the metabolic syndrome

Keyphrases

• Protective Behavior 100%
• Metabolic Syndrome 100%
• Atorvastatin 100%
• Insulin Resistance 69%
• Statins 50%
• Diabetes 30%
• Insulin Sensitivity 20%
• Statin Therapy 20%
• Adipokines 20%
• Hypertension 10%
• Clinical Trials 10%
• Type 2 Diabetes Mellitus (T2DM) 10%
• Coronary Artery Disease 10%
• Tumor Necrosis Factor-α 10%
• Adiponectin 10%
• Clinical High Risk 10%
• Beneficial Effects 10%
• Type 1 Diabetes Mellitus (T1DM) 10%
• Obese Patients 10%
• Hypertensive Patients 10%
• Serum Levels 10%
• LDL Cholesterol 10%
• Risk for Cardiovascular Diseases 10%
• Type 2 Diabetic Patients 10%
• Commercially Available 10%
• Antihyperlipidemic 10%
• 3-hydroxy-3-methylglutaryl-coenzyme A 10%
• Reductase Inhibitors 10%
• Promising Strategies 10%
• Insulin Sensitizers 10%
• Clinical Observation 10%
• Goal Attainment 10%
• How about 10%
• Impaired Glucose Intolerance 10%
• Simple Strategy 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Metabolic Syndrome X 100%
• Pravastatin 100%
• Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor 40%
• Insulin Resistance 40%
• Statin (Protein) 30%
• Hyperlipidemia 20%
• Clinical Study 20%
• Adipocytokine 20%
• Non Insulin Dependent Diabetes Mellitus 20%
• Coronary Artery Disease 10%
• Tumor Necrosis Factor 10%
• Adiponectin 10%
• Clinical Trial 10%
• Diabetes Mellitus 10%
• Low Density Lipoprotein Cholesterol 10%
• Oxidoreductase 10%
• HMG-CoA 10%
• Glucose Intolerance 10%
• Cardiovascular Disease 10%